Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention

Eric L. Simpson (Lead / Corresponding author), Joanne R. Chalmers, Jon M. Hanifin, Kim S. Thomas, Michael J. Cork, W. H. Irwin McLean, Sara J. Brown, Zunqiu Chen, Yiyi Chen, Hywel C. Williams

    Research output: Contribution to journalArticlepeer-review

    591 Citations (Scopus)
    415 Downloads (Pure)



    Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization.

    Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates.

    We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator.

    Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups.

    The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.
    Original languageEnglish
    Pages (from-to)818-823
    Number of pages6
    JournalJournal of Allergy and Clinical Immunology
    Issue number4
    Publication statusPublished - Oct 2014


    Dive into the research topics of 'Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention'. Together they form a unique fingerprint.

    Cite this